ID
6181
Beskrivning
ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588
Länk
http://clinicaltrials.gov/ct2/show/record/NCT00952588
Nyckelord
Versioner (4)
- 2011-11-14 2011-11-14 -
- 2013-12-06 2013-12-06 - Martin Dugas
- 2014-04-11 2014-04-11 - Julian Varghese
- 2014-12-16 2014-12-16 - Martin Dugas
Uppladdad den
16 december 2014
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility AZD1152 and LDAC in AML
Eligibility AZD1152 and LDAC in AML
- StudyEvent: Eligibility
Beskrivning
Exclusion criteria
Alias
- UMLS CUI-1
- C0680251
Beskrivning
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Datatyp
boolean
Alias
- UMLS CUI-1
- C2348568
Beskrivning
Administration of LDAC is clinically contraindicated
Datatyp
boolean
Alias
- UMLS CUI-1
- C1301624
- UMLS CUI-2
- C0010711
Beskrivning
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Datatyp
boolean
Alias
- UMLS CUI-1
- C0023487
Beskrivning
Patients with blast crisis of chronic myeloid leukaemia
Datatyp
boolean
Alias
- UMLS CUI-1
- C0023473
- UMLS CUI-2
- C0005699
Similar models
Eligibility AZD1152 and LDAC in AML
- StudyEvent: Eligibility
C0600558 (UMLS CUI-2)
C0010711 (UMLS CUI-2)
C0005699 (UMLS CUI-2)